Navigation Links
CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma

- Preliminary results to be presented on November 1, 2008 at 2008 iSBTc

Annual Meeting -

BRANFORD, Conn., Sept. 11 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, today announced that it has completed the enrollment of patients into its Phase II trial evaluating CR011-vcMMAE for the treatment of advanced melanoma. CuraGen also announced today that Phase II results from this trial will be presented during an oral session at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer (iSBTc), being held October 31 -- November 2, 2008, in San Diego, CA. The trial will be presented by Dr. Patrick Hwu, Co-Principal Investigator and Professor and Chairman of the Department of Melanoma Medical Oncology at The University of Texas, M.D. Anderson Cancer Center.

"We are very pleased with the clinical progress achieved with CR011-vcMMAE. Completing enrollment in this melanoma study ahead of schedule highlights the external support for this novel antibody-drug conjugate from our investigators," commented Dr. Timothy Shannon, President and Chief Executive Officer of CuraGen. "We expect that treatment of patients will still be ongoing in this Phase II trial at the time of iSBTc, and therefore look forward to presenting the first data from all treated patients in November, and anticipate that final results from the study will be available during the first half of 2009."

A total of 36 patients were enrolled in this Phase II open-label, multi-center trial evaluating the efficacy and safety of CR011-vcMMAE 1.88 mg/kg administered intravenously once every three weeks in patients with unresectable Stage III or Stage IV melanoma. Eligible patients had progressive disease at trial entry and may have received one prior cytotoxic regimen and any number of prior immunotherapies. Clinical efficacy endpoints include objective response rate, progression free rate, time to response and duration of response.

CuraGen is also continuing the Phase I portion of the trial evaluating the use of a weekly as well as a two out of every three week regimen of CR011-vcMMAE to explore the optimal dose and schedule of administration. Results from these more frequent dosing schedules are expected to be available in the first half of 2009.

In addition, CR011-vcMMAE is being studied in an ongoing Phase II trial in patients with metastatic breast cancer who have received previous chemotherapy. It is anticipated that preliminary results from the breast cancer trial will be presented in the first half of 2009.

CR011-vcMMAE targets glycoprotein NMB (GPNMB), which is overexpressed in a variety of cancers including melanoma, breast cancer and brain tumors. CR011-vcMMAE is an antibody-drug conjugate comprised of a fully-human monoclonal antibody against GPNMB linked to a potent tubulin destabilizing agent, monomethyl auristatin E (MMAE). The enzyme-sensitive linker, which was licensed from Seattle Genetics, is designed to be stable in the bloodstream and to release MMAE inside tumor cells, resulting in cancer cell death.

iSBTc Presentation Details

Title: Phase I/II Study of CR011-vcMMAE, an Antibody-Drug Conjugate

targeting GPNMB, for the Treatment of Patients with Advanced


Type: Oral presentation

Presenter: Dr. Patrick Hwu

Session: Tumor Targeting Monoclonal Antibodies

Date/Time: November 1, 2008 from 2:45 p.m. to 4:15 p.m.

About Melanoma

According to the American Cancer Society, it is expected that approximately 60,000 new cases of melanoma will be diagnosed, including nearly 11,000 patients diagnosed with Stage III or Stage IV disease, and an estimated 8,000 people in the U.S. will die of the disease during 2008. The prognosis for patients with advanced melanoma is poor, and studies have shown that the median survival is less than nine months.

About CuraGen

CuraGen Corporation (Nasdaq: CRGN) is a dedicated clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit

Forward-Looking Statements

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to the clinical progress of our development programs, the timing and expected results of our clinical programs, and the development and marketability of planned drugs, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including the risk that any one or more of CuraGen's drug development programs will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical company, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, uncertainty of additional funding, CuraGen's history of incurring losses and the uncertainty of achieving profitability, reliance on research collaborations and strategic alliances, competition, patent infringement claims against CuraGen's products, processes and technologies, CuraGen's ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred to in CuraGen's Quarterly Report on Form 10-Q for the quarter ended June 30, 2008, filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, CuraGen's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. CuraGen is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



Glenn Schulman, PharmD

Director of Medical Communications

(888) 436-6642

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
10. CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
11. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
Post Your Comments:
(Date:12/1/2015)... VANCOUVER , Dec. 1, 2015  Following an ... (NASDAQ: OGXI ) announced today that its Phase ... interim futility analysis of the intent-to-treat (ITT) population. In ... identified by the DMC. Both the DMC and OncoGenex ... expected in the second half of 2016, depending on ...
(Date:12/1/2015)... , Dec. 1, 2015  CytoSorbents Corporation (NASDAQ: ... commercializing its CytoSorb® blood purification technology to reduce ... world, today announced that Dr. Phillip Chan ... to participate in the LD Micro Main Event ... Conference, both of which will be held in ...
(Date:12/1/2015)... Colo. , Dec. 1, 2015 /PRNewswire/ ... ) today announced that its Chief Executive ... at the Oppenheimer Annual Healthcare Conference in ... participate in the conference through a webcast ... , --> ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Florida Hospital Tampa is the first health ... in the state of Florida. , vBloc® Therapy is a vagal blocking therapy, delivered via ... with a body mass index (BMI) of at least 40 to 45 kg, or a ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... continuing medical education (CME), today announced that the first annual School of Gastrointestinal ... , “The prevention, detection and treatment of gastrointestinal cancers are undergoing transformational change, ...
(Date:12/1/2015)... ... , ... Califia Farms , one of the fastest growing natural beverage ... honors in Beverage World Magazine’s Global Packaging Design Awards, taking home the Gold in ... as a 2015 U.S.A. Taste Champion in the American Masters of Taste Championships for ...
(Date:12/1/2015)... Middletown, PA (PRWEB) , ... December 01, 2015 ... ... separate environments; however, there are professionals who believe that with innovative technologies and ... services allows the patient to get the benefit of a dual-approach to his ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015 -- ... the company’s growing product line of food safety and seafood fraud prevention tools. ... nerka) – allow InstantLabs to offer fast, reliable species identification for the four ...
Breaking Medicine News(10 mins):